OrbiMed’s Eli Lilly LLY Stock Holding History

OrbiMed’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$4.85K	–	124
2022 Q3	$4.85K	Buy	+15,000	New	+$4.75M	0.09%	105
2017 Q1	–	Sell	-150,000	Closed	-$11M	–	140
2016 Q4	$11M	Sell	150,000 -100,000	-40%	-$7.45M	0.14%	90
2016 Q3	$20.1M	Buy	+250,000	New	+$20M	0.23%	75
2013 Q3	–	Sell	-100,000	Closed	-$4.91M	–	129
2013 Q2	$4.91M	Buy	+100,000	New	+$5.44M	0.1%	101

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OrbiMed's LLY Position: Q1 2026 in Review

OrbiMed reduced its Eli Lilly (LLY) stake by 21% in Q1 2026, selling an estimated $65.3M and leaving 236,800 shares worth $218M. The position accounts for 4.32% of the portfolio, ranked #4.

OrbiMed first reported a position in LLY in Q1 2014 and has held it in 26 quarters since. The position peaked at $324M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

OrbiMed held 236,800 shares of Eli Lilly worth $218M as of Q1 2026.
OrbiMed sold 64,400 Eli Lilly shares in Q1 2026, an estimated $65.3M.
Eli Lilly made up 4.32% of OrbiMed's portfolio in Q1 2026, its #4 holding.
OrbiMed first reported a position in Eli Lilly in Q1 2014 and has held it in 26 quarters since.
OrbiMed's Eli Lilly position peaked at $324M in Q4 2025.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.